Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML

Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
arcticnovartis

  • Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs1
  • Clinically relevant 15.2% higher MMR rate achieved with Scemblix vs. 2G TKIs1
/by
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
arcticnovartis

  • New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session
  • New ianalumab interim results from Sjögren’s Phase III extension study up to week 108 and Phase II data in systemic lupus erythematosus will be presented
/by